



13 SEP 2021

FDA ADVISORY
No. **2021-2292**

TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT : Public Health Warning Against the Purchase and Use of the following Counterfeit Drug Products:

1. Dexamethasone (Decilone® Forte) 4 mg Tablet
2. Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Bioflu®) 10 mg / 2 mg / 500 mg Tablet
3. Loperamide (Diatabs®) 2 mg Capsule
4. Loperamide HCl (Lomotil®) 2 mg Tablet
5. Loperamide (Imodium) 2 mg Capsule

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following products:




Figure 1. Dexamethasone (Decilone® Forte) 4 mg Tablet (Lot No. A022312)



AUTHENTIC



COUNTERFEIT



Counterfeit – Tablet color, blister strip, logo, security mark, knurling, print color and appearance are different from standard.

Figure 2. Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Bioflu®) 10 mg / 2 mg / 500 mg Film-Coated Tablet (Lot no. U099126)

AUTHENTIC



COUNTERFEIT



Counterfeit – Flex strip, logo, security mark, knurling, print color and appearance are different from standard.

Figure 3. Loperamide (Diatabs®) 2 mg Capsule (Lot no. U6501892)

AUTHENTIC



COUNTERFEIT



Counterfeit – The Lot No. does not conform the product specification.

Figure 4. Loperamide HCl (Lomotil®) 2 mg Tablet (Lot No. 15LMT05)

AUTHENTIC



COUNTERFEIT



Counterfeit – The Lot No. does not conform the product specification.

Figure 5. Loperamide (Imodium) 2 mg Capsule (Lot No. 65C-21)

All healthcare professionals and the general public are hereby warned as to the availability of these counterfeit drug products in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug products only from FDA-licensed establishments. Always check if a product is registered with the FDA by using the FDA Verification Portal feature accessible at <http://verification.fda.gov.ph>.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit products with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug products will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via report@fda.gov.ph, or through the online reporting facility, **eReport**, at www.fda.gov.ph/ereport. You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN:



20210826151746